Overview
Sermorelin is the biologically active GHRH(1-29)-amide fragment, comprising 29 amino acids. Sermorelin Acetate is an established name for this form and places the material within research on growth hormone-releasing hormone signaling.
Each vial contains 5 mg of Sermorelin Acetate. This material is supplied for research use only and is not a medicine or a product intended for human or animal use.
Mechanism and research
Sermorelin represents the first 29 amino acids of growth hormone-releasing hormone in an amidated fragment. It is studied in relation to the GHRH receptor and the signalling involved in growth hormone release. Its molecular identity differs from longer GHRH analogues and modified compounds with different pharmacokinetic properties.
Analytical research has examined the identification of GHRH-related peptides and their metabolites in plasma. This provides a scientific context for distinguishing intact material from degradation products. The acetate form identifies the salt form supplied here; it does not define an administration protocol.
Strength and packs
Select one vial for 5 mg total content, two vials for 10 mg, or three vials for 15 mg. Each vial retains the stated 5 mg strength.
The selected pack changes the number of individually supplied vials. It does not change the 5 mg content of an individual vial.
Scientific sources
Sermorelin MeSH record
Qualitative identification of growth hormone-releasing hormones in human plasma
Sermorelin – PubChem
GHRH receptor agonist: amidated GHRH(1-29) fragment.
Note: The dosages listed correspond to typical ranges from published research literature. They do not replace advice from a qualified researcher or physician.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.